Aminomux (pamidronate disodium): Uses, Dosage & Side Effects

What it's for (Indications)

Management of hypercalcemia (increased level of calcium in the blood) due to tumors or associated with malignancy.
Consideration should be given to the severity and symptoms of hypercalcemia.

Dosage Information

Type	Guideline
Standard	For Hypercalcemia of Malignancy: - Mild, asymptomatic hypercalcemia may be treated with vigorous saline hydration alone. Glucocorticoid therapy may also be helpful in hypercalcemia associated with hematologic malignancies. - Moderate Hypercalcemia (corrected serum calcium of approximately 12 to 13.5 mg/dL): Recommended dose is 60 to 90 mg given as a SINGLE DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (>2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency. - Severe Hypercalcemia (corrected serum calcium >13.5 mg/dL): Recommended dose is 90 mg given as a SINGLE DOSE, intravenous infusion over 2 hours.

Type

Guideline

Standard

For Hypercalcemia of Malignancy: - Mild, asymptomatic hypercalcemia may be treated with vigorous saline hydration alone. Glucocorticoid therapy may also be helpful in hypercalcemia associated with hematologic malignancies. - Moderate Hypercalcemia (corrected serum calcium of approximately 12 to 13.5 mg/dL): Recommended dose is 60 to 90 mg given as a SINGLE DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (>2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency. - Severe Hypercalcemia (corrected serum calcium >13.5 mg/dL): Recommended dose is 90 mg given as a SINGLE DOSE, intravenous infusion over 2 hours.

Safety & Warnings

Common Side Effects

Transient mild elevation of temperature (fever/pyrexia, typically at least 1°C, noted 24 to 48 hours post-administration in up to 34% of patients).
Drug-related local soft-tissue symptoms at the catheter insertion site (redness, swelling, induration, and pain on palpation) are common, especially with higher doses.
Rare ocular adverse events such as uveitis, iritis, scleritis, and episcleritis have been reported.
Consult your doctor immediately if fever persists for a long period.

Serious Warnings

Black Box Warning: Pamidronate disodium does not carry an FDA-mandated Black Box Warning. However, several serious warnings and precautions are critically important for patient safety and efficacy monitoring. Acute renal failure has been reported, particularly with rapid intravenous infusion, high cumulative doses, or in patients with pre-existing renal impairment, severe dehydration, or concomitant use of other nephrotoxic medications. Consistent monitoring of renal function, including serum creatinine, is imperative before and throughout treatment. Osteonecrosis of the jaw (ONJ) is a significant risk, primarily observed in cancer patients receiving intravenous bisphosphonates, often compounded by factors such as chemotherapy, corticosteroids, radiation therapy, poor oral hygiene, or pre-existing dental disease. A comprehensive dental examination and preventive dental work should be considered prior to initiating bisphosphonate therapy in patients with risk factors. Severe and occasionally incapacitating bone, joint, and/or muscle pain has also been reported; if such symptoms occur, discontinuation of the drug should be considered. Atypical femoral fractures have been reported with bisphosphonate use, predominantly in patients on long-term therapy. Patients presenting with new onset thigh or groin pain should be evaluated promptly to rule out a potential atypical fracture.
Use with extreme caution in patients with cardiac (heart) diseases or potential for cardiac failure, as overhydration should be avoided.
Exercise extreme caution in patients with renal (kidney) impairment or preexisting renal insufficiency due to the risk of renal toxicity, for which longer infusion times may be beneficial.
Consult your doctor before using this medication during pregnancy or while lactating.

How it Works (Mechanism of Action)

Pamidronate disodium, a potent nitrogen-containing bisphosphonate, primarily functions by inhibiting osteoclastic bone resorption. Its molecular mechanism involves adsorption onto the surface of hydroxyapatite crystals within the bone matrix, particularly at sites of active bone turnover. When osteoclasts, the bone-resorbing cells, resorb bone containing pamidronate, the drug is internalized into the osteoclast. Inside the osteoclast, pamidronate acts as an analog of pyrophosphate and specifically inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. This inhibition prevents the prenylation of crucial proteins, particularly small guanosine triphosphatases (GTPases) such as Rac1 and Rho. Prenylation is essential for the proper membrane localization and function of these GTPases, which regulate vital osteoclast activities including cell adhesion, cytoskeletal integrity, ruffled border formation, and ultimately, osteoclast survival. By disrupting these processes, pamidronate leads to osteoclast dysfunction, impairs their ability to resorb bone, and can induce osteoclast apoptosis, thereby significantly reducing the rate of bone turnover and calcium release from bone. This targeted action makes it highly effective in managing conditions characterized by excessive bone resorption, such as hypercalcemia of malignancy, Paget's disease of bone, and osteolytic bone metastases.